Protego Biopharma

Executive Summary

Protego Biopharma is a private, San Diego-based biotech company at the forefront of drug discovery for protein misfolding diseases, a class of disorders that includes numerous neurodegenerative and systemic conditions with high unmet medical need. Founded in 2017, the company leverages its proprietary platform to develop first-in-class small molecule therapies that correct protein misfolding, aiming to halt or reverse disease progression. Currently in Phase 1 stage, Protego is advancing its lead candidate through initial clinical testing while expanding its preclinical pipeline. The company's strategy focuses on rapidly validating its approach in proof-of-concept studies and establishing clinical data that could support further development or partnership opportunities. Protego's progress is marked by the recent initiation of its first-in-human Phase 1 trial, which is expected to yield initial safety, tolerability, and pharmacokinetic data in the coming quarters. The company is also preparing to advance a second candidate toward IND-enabling studies, targeting a different protein misfolding indication. With a lean team and focused pipeline, Protego represents a high-risk, high-reward investment in a biologically validated therapeutic area. Key upcoming catalysts include Phase 1 data readouts, preclinical updates, and potential partnering or financing events that could de-risk the platform and provide a path to Phase 2 development.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Initial Data Readout for Lead Candidate60% success
• Q2 2027IND Filing for Second Program50% success
• Q1 2027Partnership or Series B Financing40% success